UNITED KINGDOM: Cannabis smoke exposure, even long-term, is not positively associated with chronic obstructive pulmonary disease (COPD), lung cancer, or irreversible airway damage, according to a literature review published in the journal Breathe.
COLORADO: Long-term exposure to cannabis smoke is not associated with significant adverse effects on pulmonary function, according to clinical data published in the journal Chronic Obstructive Pulmonary Diseases.
A team of investigators led by researchers at the Colorado School of Public Health assessed the relationship between marijuana use and respiratory function in a cohort of 2,300 subjects ages 40 to 80, many of whom also smoked tobacco.
Authors reported, “Neither current nor former marijuana use was associated with increased risk of cough, wheeze, or chronic bronchitis when compared to never marijuana users. … Current and former marijuana smokers had significantly higher FEV1 (forced expiratory volume) … when compared to never users. … Both current and former marijuana use was associated with significantly less quantitative emphysema … when compared to never users, even after adjusting for age, … current tobacco smoking pack years, and BMI. … In agreement with other published studies, we also did not find that marijuana use was associated with more obstructive lung disease.”
Researchers also reported that the long-term combined use of tobacco and cannabis was not associated with any additive adverse effects on the lungs. They concluded, “Among older adults with a history of tobacco use, marijuana use does not appear to increase risk for adverse lung function. … There may be no to little increased risk of marijuana use for a further increase in respiratory symptoms or adverse effects … among those with a history of concomitant tobacco use.”
Prior longitudinal studies assessing the effects of long-term cannabis smoke exposure on lung function have similarly reported that subjects’ marijuana use history is not positively associated with increased incidences of chronic obstructive pulmonary disease (COPD), lung cancer, or with other significant detrimental effects on pulmonary function.
For more information, contact Paul Armentano, NORML Deputy Director, at: firstname.lastname@example.org. Full text of the study, “Marijuana use associations with pulmonary symptoms and function in tobacco smokers enrolled in the subpopulations and intermediate outcome measures in COPD Study (SPIROMICS),” appears in Chronic Obstructive Pulmonary Diseases.
ISRAEL: iCAN Israel-Cannabis and Aura Medical have joined forces to bring FDA approved nebulizers to the burgeoning medical cannabis market.
The Aura’s Portable Nebulizer is widely acclaimed and recommended by the nation’s top Pulmonologists and Respiratory Therapists for use in treating asthma and COPD and now will be used by millions more worldwide. The device will be marketed under the brand name “Nebican.”
Utilizing specially developed controlled dosages, the Nebican portable nebulizer is a perfect delivery system for medical cannabis. Nebican is the answer to medical practitioners and patients worldwide as demand turns towards medical cannabis to alleviate numerous ailments.
Designed with patented Vibrating Mesh Technology (VMT), Nebican is an innovative form of atomization that emits extremely thin and fog like vapor. Like air, the mist released from the inhaler can easily penetrate deep into the lungs. Pocket sized, it is portable, discreet, convenient and easy to use.
CALIFORNIA: The pulmonary consequences of regularly smoking marijuana are far less than for tobacco, according a review of the published evidence conducted by Dr. Donald P. Tashkin, emeritus professor of medicine and medical director of the pulmonary function laboratory at the University of California, Los Angeles. [Read more…]